化合物Olomoucine T21588

Product Introduction
Bioactivity


英文名: Olomoucine

描述: Olomoucine 是 Cdk2/cyclin A、Cdc2/CyclinB、CDK2/CyclinE、CDK5/p35 和 ERK1/p44 MAP 激酶的 ATP 竞争性抑制剂，IC50 分别为 7、7、7、3 和 25 µM。 Olomoucine 调节细胞周期并表现出抗黑色素肿瘤活性。

体外活性: In Rdditapes oocytes, Olomoucine (0-150 μM) inhibits prophase/metaphase transition. In CTLL-2 cells, Olomoucine (0-1000 μM) inhibits DNA synthesis and triggers a Gl arrest similar to interleukin-2 deprivation. In NSCLC MB65 cells, Olomoucine (0-100 μM) inhibits Gl/S transition[1]. Olomoucine inhibits tumor cell survival with IC50s of 32.35, 42.15, and 82.30 μM for dog, mouse B16, and human melanoma, respectively[4].

体内活性: In female Balb C− mice, Olomoucine results faster plasma concentration decreasing with 50 mg/kg (as single agent) than 16.6 mg/kg (as cassette)[3]. In dog with spontaneous melanoma, Olomoucine (8 mg/kg; i.v.) induces programmed cell death of cancer cells and results in rapid eradication of at least 68% of the tumor cells without side effects[4].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (167.59 mM)


关键字: Inhibitor | cyclindependent kinases | cdc2 | purines | cell cycle | non-small cell lung cancer cell line | MR6.5 | protein kinases | Cyclin dependent kinase | CDK | Olomoucine | xenopus laevis oocytes | proliferation | inhibit | cdk2

相关产品: Longdaysin | Vincristine | Tizaterkib | δ-Tocotrienol | A-674563 HCl (552325-73-2(free base)) | Xanthyletin | Meranzin hydrate | β,β-Dimethylacrylshikonin | Corylifol C | Manassantin B

相关库: Anti-Prostate Cancer Compound Library | Anti-Liver Cancer Compound Library | Anti-Breast Cancer Compound Library | Anti-Cancer Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Kinase Inhibitor Library | Anti-Colorectal Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library

化合物Olomoucine T21588信息由TargetMol中国为您提供，如您想了解更多关于化合物Olomoucine T21588报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途